To review the evidence for the use of open-inhaler (inhaled corticosteroid [ICS] plus long-acting β 2 -agonist [LABA] with separate add-on long-acting muscarinic antagonist [LAMA]) versus sin
This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone pro
Background Type-2-diabetes-mellitus (T2DM), often linked to obesity, raises risk of microvascular and macrovascular complications. International guidelines recommend triple-therapy to reach haemoglobi